Stay updated on Pembrolizumab in Hypermutation Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, signaling a newer version of the page content. This change reflects a minor metadata update rather than alterations to study details.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedMinor version update from v3.5.0 to v3.5.2 with no visible changes to study details or on-page content.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision: v3.4.3 released. The page content appears unchanged aside from the version label.SummaryDifference0.0%

- Check65 days agoChange DetectedResults have been posted for the study, including ORR, PFS, and OS outcomes with posting dates. The page now includes links to the study protocol and statistical analysis plan.SummaryDifference3%

- Check86 days agoChange DetectedRevision: v3.4.2 was added to the page. The government funding lapse notice and the v3.4.1 revision information were removed.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.